Gyre Therapeutics (NASDAQ:GYRE) Shares Cross Above 200 Day Moving Average - Time to Sell?

Key Points

• Gyre Therapeutics shares rose 8.6%, trading at $7.09 and moving above their 200-day moving average of $7.01, with 125,144 shares changing hands.
• Analyst sentiment remains negative: one analyst rates the stock “Hold” and another “Sell,” resulting in a consensus “Reduce” rating.
• The company missed quarterly EPS expectations, reporting a loss of $0.12 per share versus the projected $0.06 loss, despite revenue of $29.11 million exceeding estimates.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $7.01 and traded as high as $7.10. Gyre Therapeutics shares last traded at $7.09, with a volume of 125,144 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Zacks Research upgraded shares of Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 6th. Finally, Wall Street Zen lowered shares of Gyre Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, October 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Reduce".

Gyre Therapeutics Stock Up 8.6%

The company has a market capitalization of $790.61 million, a P/E ratio of -33.76 and a beta of 1.89. The business has a fifty day moving average price of $6.80 and a 200 day moving average price of $7.01.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The firm had revenue of $29.11 million for the quarter, compared to the consensus estimate of $26.49 million. As a group, equities analysts forecast that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds have recently made changes to their positions in the business. Bank of America Corp DE acquired a new position in Gyre Therapeutics during the second quarter worth $83,000. Deutsche Bank AG bought a new position in Gyre Therapeutics in the second quarter valued at $118,000. Dimensional Fund Advisors LP grew its position in Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after purchasing an additional 14,365 shares in the last quarter. Bank of New York Mellon Corp grew its position in Gyre Therapeutics by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock valued at $301,000 after purchasing an additional 1,941 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in Gyre Therapeutics by 1.8% in the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company's stock valued at $1,244,000 after buying an additional 2,967 shares during the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company's lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.